1. Salahuddin S.Z., Ablashi D.V., Markham P.D., Josephs S.F., Sturzenegger S., Kaplan M., Halligan G., Biberfeld P., Wong-Staal F., Kramarsky B., et al. Isolation of a new virus, HBLV, in patients
with lymphoproliferative disorders. Science. 1986;234:596–601.
2. Ablashi D., Agut H., Alvarez-Lafuente R., Clark D.A., Dewhurst S., DiLuca D., Flamand L., Frenkel N., Gallo R., Gompels U.A., et al. Classification of HHV-6A and HHV-6B as distinct viruses.
Arch. Virol. 2014;159:863–870
3. Agut H., Bonnafous P., Gautheret-Dejean A. Human Herpesviruses 6A, 6B, and 7. Microbiol Spectr. 2016;4(3)
4. Agut H., Bonnafous P., Gautheret-Dejean A. Laboratory and clinical aspects of human herpesvirus 6 infections. Clin Microbiol Rev. 2015;28:313-35
5. Weaver, G. C., Arya, R., Schneider, C. L., Hudson, A. W., & Stern, L. J. (2022). Structural Models for Roseolovirus U20 And U21: Non-Classical MHC-I Like Proteins From HHV-6A, HHV-6B, and
HHV-7. Frontiers in immunology, 13, 864898.
6. Mori Y., Zerr D.M., Flamand L., Pellett P.E. 2022. Human herpesviruses 6A, 6B and, 7, p 696-728. In , Howley PM, Knipe DM , Cohen JI, Damania BA (ed), Fields Virology, 7th ed, vol 2.
Wolters Kluwer/Lippincot Williams & Wilkins, Philadelphia, PA.
7. Catusse J., Spinks J., Mattick C., Dyer A., Laing K., Fitzsimons C., Smit M.J., Gompels U.A. Immunomodulation by herpesvirus U51A chemokine receptor via CCL5 and FOG-2 down-regu-
lation plus XCR1 and CCR7 mimicry in human leukocytes. Eur J Immunol. 2008;38:763-77.
8. Tesini B.L., Epstein L.G., Caserta M.T. Clinical impact of primary infection with roseoloviruses. Curr Opin Virol. 2014;9:91-6
9. Komaroff A.L., Rizzo R., Ecker J.L. Human Herpesviruses 6A and 6B in Reproductive Diseases. Front Immunol. 2021;12:648945
10. Pantry S.N., Medveczky P.G. Latency, Integration, and Reactivation of Human Herpesvirus-6. Viruses. 2017;9:194
11. Kaufer B.B., Flamand L. Chromosomally integrated HHV-6: impact on virus, cell and organismal biology. Curr Opin Virol. 2014;9:111-8.
12. Dewin D.R., Catusse J., Gompels U.A. Identification and characterization of U83A viral chemokine, a broad and potent beta-chemokine agonist for human CCRs with unique selectivity and
inhibition by spliced isoform. J Immunol. 2006;176(1):544-56
13. Flamand L., Menezes J. Cyclic AMP-responsive element-dependent activation of Epstein-Barr virus zebra promoter by human herpesvirus 6. J Virol. 1996;70:1784-91
14. Caserta M.T., Mock D.J., Dewhurst S. Human herpesvirus 6. Clin Infect Dis. 2001;33:829-33.
15. Wang X., Patel S.A., Haddadin M., Cerny J. Post-allogeneic hematopoietic stem cell transplantation viral reactivations and viremias: a focused review on human herpesvirus-6, BK virus and
adenovirus. Ther Adv Infect Dis. 2021;8:2049936121101802
16. Calle A.M., Aguirre N., Ardila J.C., Cardona Villa R. DRESS syndrome: A literature review and treatment algorithm. World Allergy Organ J. 2023;16:100673
17. Leveque N., Boulagnon C., Brasselet C., Lesaffre F., Boutolleau D., Metz D., Fornes P., Andreoletti L. A fatal case of Human Herpesvirus 6 chronic myocarditis in an immunocompetent adult.
J Clin Virol. 2011;52:142-5
18. Gravel A., Dubuc I., Morissette G., Sedlak R.H., Jerome K.R., Flamand L. Inherited chromosomally integrated human herpesvirus 6 as a predisposing risk factor for the development of angina
pectoris. Proc Natl Acad Sci U S A. 2015;112:8058-63
19. Agut H., Bonnafous P., Gautheret-Dejean A. Update on infections with human herpesviruses 6A, 6B, and 7. Med Mal Infect. 2017;47:83-91
20. Landry M.L., Leland D. 2016. Primary Isolation of Viruses, p 79-94. In, Loeffelholz MJ, Hodinka RL, Young S.A., Pinsky B.A (ed), Clinical Virology Manual, 5 th ed, ASM Press, Washington,
DC
21. Leland D.S., Relich R.F. 2016. Viral Antigen Detection. p 95-104. In, Loeffelholz MJ, Hodinka RL, Young S.A., Pinsky B.A (ed), Clinical Virology Manual, 5 th ed, ASM Press, Washington, DC
22. Barks J. 2016. DNA Sequencing for Clinical and Public Health Virology: Some Assembly Required. p 173-200. In, Loeffelholz M.J., Hodinka R.L., Young S.A., Pinsky B.A (ed), Clinical Viro-
logy Manual, 5 th ed, ASM Press, Washington, DC
23. Xia D., Wadford D.A., Preas C.P., Schnurr D.P. 2016. Serologic (Antibody Detection)Methods. p 105-116. In, Loeffelholz M.J., Hodinka R.L., Young S.A., Pinsky B.A (ed), Clinical Virology
Manual, 5 th ed, ASM Press, Washington, DC
24. Prichard M.N., Whitley R.J. The development of new therapies for human herpesvirus 6. Curr Opin Virol. 2014;9:148-53.
25. Suga S., Yoshikawa T., Nagai T., Asano Y. Clinical features and virological findings in children with primary human herpesvirus 7 infection. Pediatrics. 1997;99:E4
26. Caserta M.T., Hall C.B., Schnabel K., Long C.E., D’Heron N. Primary human herpesvirus 7 infection: a comparison of human herpesvirus 7 and human herpesvirus 6 infections in children.
J Pediatr. 1998;133:386-9.
27. Tanaka K., Kondo T., Torigoe S., Okada S., Mukai T., Yamanishi K. Human herpesvirus 7: another causal agent for roseola (exanthem subitum). J Pediatr. 1994;125:1-5
28. Leach C.T. Human herpesvirus-6 and 7 infections in children: agents of roseola and other syndromes. Curr Opin Pediatr. 2000;12:269-74.
29. Bray F., Ferlay J., Soerjomataram I., Siegel R.l., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
CA Cancer J Clin 2018; 68: 394-424.
30. Calabro M.L., Sarıd R. Human Herpesvirus 8 and Lymphoproliferative Disorders. Mediterr J Hematol Infect Dis 2018;10: e2018061
31. Arvin A., Campadelli-Fiume G., Mocarski E., Moore P.S., Roizman B., Whitley R., Yamanishi K., editors. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge:
Cambridge University Press; 2007.
32. Labo N., Whitby D. Kaposi’s Sarcoma-Associated Herpesvirus: Epidemiology and Clinical Features of Related Cancer. In: Viruses and Human Cancer. Springer Science+Business Media, New
York, 2014: 323–340.6
33. Baresova P., Pitha P.M., Lubyova B. Distinct roles of Kaposi’s sarcoma-associated herpesvirus-encoded viral interferonregulatory factors in inflammatory response and cancer. J Virol.
2013;87:9398–9410
34. Mercader M., Taddeo B., Panella J.R., et al. Induction of KSHV lytic cycle replication by inflammatory cytokinesproduced by HIV-1-infected T cells. Am J Pathol 2000;156:1961–71
35. Cavallin L.E., Goldschmidt-Clermont P., Mesrı E.A. Molecular and cellular mechanisms of KSHV oncogenesis of Kaposi’s sarcoma associated with HIV/AIDS. PLoS 2014;10: e1004154
36. Warren-Gash C., Forbes H.J., Williamson E., et al. Human herpesvirus infections and dementia or mild cognitive impairment: a systematic review and meta-analysis. Sci Rep. 2019;9:4743
37. Nagy S., Gyulai R., Kemeny L., et al. Iatrogenic Kaposi’s sarcoma: HHV-8 positivity persists but the tumors regress almost completely without immunosuppressive therapy. Transplantation
2000;69:2230
38. Kimball L.E., Casper C., Koelle D.M., et al. Reduced levels of neutralizing antibodies to Kaposi sarcoma-associated herpesvirus in persons with a history of Kaposi sarcoma. J Infect Dis
2004;189:2016
39. Mulama D.H., Mutsvunguma L.Z., Totonchy J., et al. A multivalent Kaposi sarcoma-associated herpesvirus-like particle vaccine capable of eliciting high titers of neutralizing antibodies in
immunized rabbits. Vaccine. 2019;37:4184–4194.
40. Pellett P.E., Ablashi D.V., Ambros P.F., Agut H., Caserta M.T., Descamps V., Flamand L., Gautheret-Dejean A., Hall C.B., Kamble R.T., Kuehl U., Lassner D., Lautenschlager I., Loomis K.S.,
Luppi M., Lusso P., Medveczky P.G., Montoya J.G., Mori Y., Ogata M., Pritchett J.C., Rogez S., Seto E., Ward K.N., Yoshikawa T., Razonable R.R. Chromosomally integrated human herpesvirus
6: questions and answers. Rev Med Virol. 2012;22:144-55
41. Andreoni M., Sarmati L., Nicastri E., et al. Primary Human Herpesvirus 8 Infection in Immunocompetent Children. JAMA. 2002;287:1295–1300
42. Wang Q.J., Jenkıns F.J., Jacobson L.P., Kingsley L.A., Day R.D., Zhang Z.W., et al. Primary human herpesvirus infection generates a broadly specific CD8 (+) T-cell response to viral lytic cycle
proteins. Blood. 2001;97:2366-73
43. Iftode N., Rădulescu M.A., Aramă Ș.S., Aramă V. Update on Kaposi sarcoma-associated herpesvirus (KSHV or HHV-8) review. Rom J Intern Med. 2020;58:199-208.
44. Reichart P.A., Khongkhunthian P., Bendick C. Oral manifestations in HIV-infected individuals from Thailand and Cambodia. Medical Microbiology and Immunology 2003; 192:157–60
45. Fatahzadeh M., Schwartz R.A. Oral Kaposi’s sarcoma: a review and update. Int J Dermatol. 2013;52:666–672
46. Zeinaty P.E., Lebbé C., Delyon J. Endemic Kaposi’s Sarcoma. Cancers (Basel). 2023;15(3):872.
47. Denis D., Seta V., Regnier-Rosencher E., Kramkimel N., Chanal J., Avril M.F. et al. A fifth subtype of Kaposi’ssarcoma, classic Kaposi’s sarcoma in men who have sex with men: a cohort study
in Paris. J. Eur. Acad. Dermatol. Venereol. 2018;32:1377–84
48. Iscovich J., Boffetta P., Winkelmann R., Brennan P., Azizi E., et al. Classic Kaposi’s sarcoma in Jews living in Israel, 1961–1989: a population-based incidence study. AIDS. 1998;12:2067
49. Maurer T., Ponte M., Leslie K. HIV-associated Kaposi’s sarcoma with a high CD4 count and a low viral load. N Engl JMed. 2007;357:1352–53
50. Mikulska M., Balletto E., Mularoni A. Human herpesvirus 8 and Kaposi sarcoma: how should we screen and manage the transplant recipient? Curr Opin Infect Dis. 2021;34:646-653
51. Bigi R., Landis J.T., An H., Caro-Vegas C., Raab-Traub N., Dittmer D.P. Epstein-Barr virus enhances genome maintenance of Kaposi sarcoma-associated herpesvirus. Proc Natl Acad Sci U S
A. 2018;115:11379-87
52. Soulier J., Grollet L., Oksenhendler E., Cacoub P., Cazals-Hatem D., Babinet P., et al. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood.
1995;86:1276–1280
53. Kahouli S., Zahid H., Benkirane M., Messaoudi N. Association between Kaposi´s sarcoma and multiple myeloma: is it caused by HHV-8?. Pan Afr Med J. 2020;36:85.
54. Tedeschi R., Dillner J., Paoli P. Laboratory Diagnosis of Human Herpesvirus 8 Infection in Humans. Eur J ClinMicrobiol Infect Dis. 2002;21:831–844
55. Manners O., Murphy J.C., Coleman A., Hughes D.J., Whitehouse A. Contribution of the KSHV and EBV lyticcycles to tumourigenesis. Curr Opin Virol. 2018;32:60–70
56. Chen J., Dai L., Goldstein A., Zhang H., Tang W., Forrest C, et al. Identification of new antiviral agents againstKaposi’s sarcoma-associated herpesvirus (KSHV) by high-throughput drug
screening reveals the role of histamine-related signaling in promoting viral lytic reactivation. PLoS Pathog. 2019;15:e1008156
57. Lebbe C., Garbe C., Stratigos A.J., Grob J.J., Pages C. Diagnosis and treatment of Kaposi’s sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC). Eur J Cancer.
2019;114:117–27
58. Chan K., Lade S., Prince H., Harrison S. Update and new approaches in the treatment of Castleman disease. J BloodMed. 2016;7:145–158